| 000 | 01871 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250516030054.0 | ||
| 264 | 0 | _c20130808 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1873-2496 | ||
| 024 | 7 |
_a10.1016/j.urolonc.2010.09.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKusuda, Yuji | |
| 245 | 0 | 0 |
_aPrognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. _h[electronic resource] |
| 260 |
_bUrologic oncology _cJan 2013 |
||
| 300 |
_a42-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 |
_aBone Neoplasms _xmetabolism |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xmetabolism |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunoenzyme Techniques |
| 650 | 0 | 4 |
_aKidney Neoplasms _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Grading |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNephrectomy _xmortality |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 |
_aPhenylurea Compounds _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aMiyake, Hideaki | |
| 700 | 1 | _aBehnsawy, Hosny M | |
| 700 | 1 | _aFukuhara, Tadashi | |
| 700 | 1 | _aInoue, Taka-aki | |
| 700 | 1 | _aFujisawa, Masato | |
| 773 | 0 |
_tUrologic oncology _gvol. 31 _gno. 1 _gp. 42-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.urolonc.2010.09.008 _zAvailable from publisher's website |
| 999 |
_c20668864 _d20668864 |
||